Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 7364 matches for

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

COVID vaccine vial © John Cairns

Similar stories

T cell responses to monkeypox play a part in protecting against infection

A new study, led by researchers at the CAMS Oxford Institute in the Nuffield Department of Medicine and TIDU in the MRC Weatherall Institute of Molecular Medicine, has found that specific T cells could have an impact on the long-term protective responses to future infection.

More effective and affordable treatment strategies for Hepatitis C

Beyond the Ivory Tower event: Participants explore what it means to decolonise global health

MBRRACE-UK report shows rate of stillbirths and neonatal deaths decreased in 2023 but persistent inequalities remain

Study identifies key immune structures in the gut that may drive coeliac disease

First participant recruited to pioneering UK trial in global effort to tackle early causes of Parkinson’s